| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2452043A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/09/2003 | CA2452030A1 Sustained release pharmaceutical composition |
| 01/09/2003 | CA2451959A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | CA2451955A1 Antibodies to opgl |
| 01/09/2003 | CA2451850A1 Medicinal compositions |
| 01/09/2003 | CA2451846A1 Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
| 01/09/2003 | CA2451795A1 Cell-based high-throughput screening methods |
| 01/09/2003 | CA2451739A1 Hcv e1e2 vaccine compositions |
| 01/09/2003 | CA2451728A1 Zonisamide use in headache |
| 01/09/2003 | CA2451699A1 Compositions and methods for inhibiting platelet activation and thrombosis |
| 01/09/2003 | CA2451129A1 Glaucoma treatments with reduced hyperpigmentation |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451039A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 01/09/2003 | CA2451037A1 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2450354A1 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | CA2447280A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273305A1 Medical preparation for inhalation comprising Antithrombin for treating inflammatory lung diseases and ARDS |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272665A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/08/2003 | EP1272647A1 Multivalent antibodies and uses therefor |
| 01/08/2003 | EP1272641A2 Serine-threonine kinase |
| 01/08/2003 | EP1272638A2 Drug metabolizing enzymes |
| 01/08/2003 | EP1272637A1 A METHOD FOR SCREENING FOR AUTOIMMUNE DISEASE BY IDENTIFYING POLYMORPHISMS IN IL-12 p40 |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272614A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 01/08/2003 | EP1272530A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272517A2 Multiprotein-complexes comprising a nmda receptor and uses thereof |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272509A2 Prion-binding peptidic ligands and methods of using same |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272479A2 Novel compounds for enhancing chemotherapy |
| 01/08/2003 | EP1272468A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 01/08/2003 | EP1272455A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/08/2003 | EP1272230A1 An injectable bone mineral substitute material |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |
| 01/08/2003 | EP1272220A1 Formulation for the prevention of cardiovascular disease |
| 01/08/2003 | EP1272219A1 New combination of a betablocker and a cholesterol-lowering agent |
| 01/08/2003 | EP1272218A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 01/08/2003 | EP1272209A1 Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| 01/08/2003 | EP1272200A1 Divided dose therapies with vascular damaging activity |
| 01/08/2003 | EP1272197A2 Combination of lecithin with ascorbic acid |
| 01/08/2003 | EP1272193A2 Synergistic methods and compositions for treating cancer |
| 01/08/2003 | EP1272188A2 Use of egfr tyrosine kinase inhibitors for treating bresta cancer |
| 01/08/2003 | EP1272186A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 01/08/2003 | EP1272184A2 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 01/08/2003 | EP1272183A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 01/08/2003 | EP1272177A1 Method and formulation for treating resistance to antihypertensives and related conditions |
| 01/08/2003 | EP1272176A1 Adamantyl derivatives as anti-cancer agents |
| 01/08/2003 | EP1272174A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor |
| 01/08/2003 | EP1272170A1 Ocular growth and nicotinic antagonists |
| 01/08/2003 | EP1272156A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials |
| 01/08/2003 | EP1272154A1 Composition for improving skin lipid barrier function |
| 01/08/2003 | EP1098665B1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/08/2003 | EP1021404B1 Azetidinone derivatives for the treatment of hcmv infections |
| 01/08/2003 | EP1001677A4 A novel method for treating epidermal or dermal conditions |
| 01/08/2003 | EP0946175B1 USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS |
| 01/08/2003 | EP0906107B1 Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
| 01/08/2003 | EP0796107B1 Sunscreen-wound healing composition |
| 01/08/2003 | CN1390257A Transfer compounds, the production and the use thereof |
| 01/08/2003 | CN1390232A Human beta-secretase enzyme, inhibitor, and its composition and use |
| 01/08/2003 | CN1390215A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitor |
| 01/08/2003 | CN1390201A Cyclic amine compounds as CCR5-antagonists |
| 01/08/2003 | CN1390196A Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 01/08/2003 | CN1390193A Novel dicarboxylic acid derivatives with pharmaceutical properties |
| 01/08/2003 | CN1390142A Taxane prodrugs |
| 01/08/2003 | CN1390139A Oncolytic combinations for the treatment of cancer |
| 01/08/2003 | CN1390136A Vaccine against nepatitis B virus and human papilloma virus |
| 01/08/2003 | CN1390130A Glucosamine and egg for reducing inflammation |
| 01/08/2003 | CN1390126A Methods of treating and/or suppressing weight gain |
| 01/08/2003 | CN1390122A Tissue factor antagonists and methods of use thereof |
| 01/08/2003 | CN1390118A Dextrose and insulin fluid formulation for intravenous infusion |
| 01/08/2003 | CN1390091A Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and composition containing the same |
| 01/08/2003 | CN1098249C Use of ubimec or medicinal composition containing ubimec for treatment virus hepatitis |
| 01/08/2003 | CN1098104C New oral pharmaceutical dosage form |
| 01/08/2003 | CN1098103C Pharmaceutical use of sympathetic human white-cell interferon |
| 01/07/2003 | US6504022 Human bad polypeptides, encoding nucleic acids and methods of use |
| 01/07/2003 | US6503945 Nontoxic, drug delivery, gene therapy; therapy of cystic fibrosis |
| 01/07/2003 | US6503939 Combination regimens using 3,3-substituted indoline derivatives |
| 01/07/2003 | US6503893 Method of treating hyperproliferative diseases using active vitamin D analogues |
| 01/07/2003 | US6503889 Especially capecitabine, gemcitabine, CPT-11 or pemetrexed |
| 01/07/2003 | US6503882 Treatment of HIV |
| 01/07/2003 | US6503733 Polynucleotides which identify and encode NANCH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NANCH and a method for producing NANCH. Agonists, antibodies |
| 01/07/2003 | US6503713 Methods for identifying RNA binding compounds |
| 01/07/2003 | US6503536 Mixture with solvent and hydrophobic carrier |
| 01/07/2003 | US6503529 Blood type methods and dietary supplements |
| 01/07/2003 | US6503507 Oxygen activatable formulations for disinfection or sterilization |
| 01/07/2003 | US6503506 Nutrient therapy for immuno-compromised patients |
| 01/07/2003 | CA2192481C Drug salts |
| 01/07/2003 | CA2149055C Antitumoral compositions containing taxan derivatives |
| 01/06/2003 | CA2392288A1 Pharmaceutical preparation for the inhalation of antithrombin in anti-inflammatory lung diseases and ards |
| 01/06/2003 | CA2392187A1 Combination preparation for the therapy of immunological diseases |